Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
Relapsed and refractory multiple myeloma (MM) is defined as progression during anticancer therapy, or within 60 days of therapy completion. Patients with double resistance to bortezomib and lenalidomide that is two key anti-myeloma drugs are considered to have a very poor prognosis, and new regimens...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-10-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/152 |